Market Overview

UPDATE: Credit Suisse Initiates PDL Biopharma at Neutral on Dividend Continuity Questions

Related PDLI
US Stock Futures Mostly Flat Ahead Of Housing Data
PDL BioPharma Announces Successful Conclusion Of Debt Financing Agreement With Durata Therapeutics

Credit Suisse initiated coverage on PDL Biopharma (NASDAQ: PDLI) with a Neutral rating and a $6.50 price target.

Credit Suisse noted, "PDLI is unique among biotech companies, collecting royalties from some of the industry's biggest blockbuster antibodies and paying investors a high dividend, which we believe is fully reflected in its price. PDLI's value is primarily derived from Roche's antibody products, but increasingly it fortunes are tied to Eli Lilly's solanezumab. … PDLI is also leveraged to outperform Roche's products, for example Perjeta and T-DM1. We also expect an update to PDLI's plans to return capital to investors, potentially on its year-end conference call, which could include a special dividend."

PDL Biopharma closed at $7.83 on Monday.

Latest Ratings for PDLI

May 2013Piper JaffrayInitiates Coverage onNeutral
Mar 2013JP MorganMaintainsNeutral
Jan 2013Credit SuisseDowngradesNeutralUnderperform

View More Analyst Ratings for PDLI
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (PDLI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional